Equillium, Inc. (EQ)

NASDAQ: EQ · IEX Real-Time Price · USD
1.621
-0.109 (-6.30%)
Apr 19, 2024, 2:34 PM EDT - Market open
-6.30%
Market Cap 58.34M
Revenue (ttm) 36.08M
Net Income (ttm) -13.34M
Shares Out 35.25M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE 3.44
Dividend n/a
Ex-Dividend Date n/a
Volume 86,970
Open 1.720
Previous Close 1.730
Day's Range 1.610 - 1.794
52-Week Range 0.450 - 3.250
Beta 1.67
Analysts Strong Buy
Price Target 3.90 (+140.59%)
Earnings Date May 9, 2024

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lu... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2018
Employees 44
Stock Exchange NASDAQ
Ticker Symbol EQ
Full Company Profile

Financial Performance

In 2023, Equillium's revenue was $36.08 million, an increase of 128.97% compared to the previous year's $15.76 million. Losses were -$13.34 million, -78.64% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for EQ stock is "Strong Buy." The 12-month stock price forecast is $3.9, which is an increase of 140.59% from the latest price.

Price Target
$3.9
(140.59% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

16 days ago - Business Wire

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

18 days ago - Business Wire

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

24 days ago - Business Wire

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

4 weeks ago - Business Wire

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

4 months ago - Business Wire

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammat...

5 months ago - Business Wire

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

5 months ago - Business Wire

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato...

5 months ago - Business Wire

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammat...

6 months ago - Business Wire

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory diso...

6 months ago - Business Wire

Equillium to Host Analyst & Investor Day

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

7 months ago - Business Wire

Equillium to Present at the JonesTrading 2023 Healthcare Summit

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

7 months ago - Business Wire

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

7 months ago - Business Wire

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

8 months ago - Business Wire

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

9 months ago - Business Wire

Equillium Announces $7.5 Million Share Repurchase Program

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

9 months ago - Business Wire

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

11 months ago - Business Wire

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #celiacdisease--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therape...

1 year ago - Business Wire

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

1 year ago - Business Wire

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to ...

1 year ago - Business Wire

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

1 year ago - Business Wire

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

1 year ago - Business Wire

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato...

1 year ago - Business Wire

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

1 year ago - Business Wire

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...

1 year ago - Business Wire